QNCX · As filed with the SEC
Quince Therapeutics cash flow statement, by fiscal year
The statement as Quince Therapeutics presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
CONSOLIDATED STATEMENTS OF CASH FLOWS · USD
| USD | FY2025 Year ended Dec 31, 2025 | FY2024 Year ended Dec 31, 2024 |
|---|---|---|
| Cash flows from operating activities | ||
| Net Loss | (83,979,000) | (56,828,000) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Stock based compensation | 5,105,000 | 4,746,000 |
| Depreciation and amortization | 142,000 | 186,000 |
| Change in the fair value of contingent consideration liabilities | 7,639,000 | 3,985,000 |
| Change in fair value of debt, net | 1,809,000 | 1,709,000 |
| Change in fair value of warrants | 21,470,000 | 0 |
| Non-cash goodwill impairment charge | 0 | 17,130,000 |
| Reclassification of cumulative translation adjustment to net income | (477,000) | 0 |
| Amortization of discount on available-for-sale investments | (1,014,000) | (2,348,000) |
| Change in deferred tax liabilities | (4,963,000) | 0 |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | 2,957,000 | (1,711,000) |
| Right of use assets, operating leases and operating lease liabilities | 104,000 | (135,000) |
| Other assets | 4,204,000 | (741,000) |
| Accounts payable | (940,000) | 927,000 |
| Accrued expenses and other current liabilities | 5,776,000 | 1,067,000 |
| Other liabilities | 742,000 | 109,000 |
| Net cash used in operating activities | (41,425,000) | (31,904,000) |
| Cash flow from investing activities: | ||
| Purchase of investments | (34,418,000) | (89,562,000) |
| Proceeds from maturities of investments | 57,997,000 | 111,727,000 |
| Purchase of property and equipment | (352,000) | (257,000) |
| Net cash provided by investing activities | 23,227,000 | 21,908,000 |
| Cash flows from financing activities: | ||
| Payment of contingent consideration | 0 | (5,000,000) |
| Proceeds from issuance of common stock, common warrants, and pre-funded warrants pursuant to private placement offering, net of issuance costs | 11,426,000 | 0 |
| Proceeds from issuance of common stock upon public offering, net of issuance costs | 6,263,000 | 0 |
| Proceeds from issuance of common stock upon exercise of stock options | 220,000 | 225,000 |
| Net cash provided by (used in) financing activities | 17,909,000 | (4,775,000) |
| Effect of exchange rate changes on cash | (114,000) | 231,000 |
| Net decrease in cash and cash equivalents | (403,000) | (14,540,000) |
| Cash and cash equivalents at beginning of period | 6,212,000 | 20,752,000 |
| Cash and cash equivalents at end of period | 5,809,000 | 6,212,000 |
| Supplemental disclosures of non-cash information: | ||
| Interest payment on debt | 234,000 | 0 |
| Right-of-use assets obtained in exchange for new operating lease liabilities | 0 | 216,000 |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.